#1Improving Patient Outcomes In Critical Care Settings Developing cost-effective, rapid, near-patient diagnostic products utilizing Symphony System wyp DIAGNOSTICS#2Disclaimer Forward-looking Statements This presentation contains statements that the Company believes are "forward-looking statements" within the meaning of the Private Litigation Reform Act. Forward-looking statements in this presentation include, without limitation, the expected nature and timing of the Company's planned FDA submission and related plans for clinical study expansion, whether the Company's cash position will be sufficient to fund operations needed to achieve regulatory approval and initial commercialization of the Symphony IL-6 Test, and whether such regulatory approval will actually occur. Forward-looking statements may be identified by words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "suggest", "will," and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may be materially different from any future results or performance suggested by the forward-looking statements in this release. This presentation speaks as of the date indicated. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company's expectations of results or any future change in events. bluejay DIAGNOSTICS Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 2#3Bluejay Overview Clinical Stage Diagnostic Company Developing the Symphony TM Product Pipeline Rapidly measuring levels of Interleukin-6 (IL-6) with our initial focus on sepsis triage and monitoring DO Novel Proprietary Platform ●●● 00 Symphony™ Product Lead Candidate: IL-6 Assay Market Opportunity Commercial Strategy $ Capital Efficient Model bluejay DIAGNOSTICS Uses whole blood (no pre-processing) Results in ~20 minutes Completed initial clinical studies for measuring IL-6 in critical care settings Conducting additional studies to support planned 510(k) FDA submission Symphony™ Product Pipeline addresses multi-billion-dollar market Near-patient testing (NPT) for monitoring of disease progression Sales model initially targets clinical sites and commercial partnerships Large, well-respected clinical sites are built-in commercial customers No debt, $5.1 M in cash as of June 30, 2023 The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 3#4Sepsis is Life Threatening and Time Critical Mortality increases 8% every hour appropriate treatment is delayed ¹ Sepsis Challenging to identify at risk patients in early stage since symptoms mimic many conditions HIGHEST CHANCE FOR FULL RECOVERY AT THIS STAGE ●●● Earlier detection is needed to prevent patients from progressing to septic shock and death Sepsis is a leading cause of death in the U.S. Sepsis is one of most costly conditions to treat: DIAGNOSTICS Septic Shock Patients rapidly deteriorate at this most dangerous stage, with >40% mortality¹ ~80% OF DEATHS COULD BE PREVENTED WITH RAPID DIAGNOSIS¹ 1.7m+¹ (US) and 48.9m³ (global) people/year get sepsis Sources: 1. Sepsis Alliance; 2. The Lancet Respiratory Medicine, 2017 Vol. 5 (6) p.524-534; 3. Whttps://www.who.int/news-room/fact-sheets/detail/sepsis Cost to treat is more than $62B2/year (US) ~350k¹ (US) and 11m³ (global) people die/year 3rd leading cause of death¹ (US) and 20% of all global deaths³ #1 cost of hospitalization in US² Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 4#5Current Sepsis Assessment Methods are Complex and Slow No single standard : Multiple measurements: Hours to assess the risk and diagnose the patient Increase in Mortality DIAGNOSTICS 150 100 50 O Patient Exhibiting Sepsis Symptoms Abnormal Heart and Respiratory Rate, Fever, Rash and Skin Changes, Leg Pain, Cold Hands and Feet 0 Current 0 Our Way Hospitalization of patients with symptoms Full blood count, C-reactive protein, MAP, Lactate, and Sequential Organ Failure Assessment (SOFA score) are considered. Typically Several Hours (potentially 4-8 hours) Bluejay Solution IL-6 results in 20 mins 8 1 Mortality increases 8% every hour appropriate treatment is delayed¹ Mortality Risk (%) 16 2 Hrs from hospitalization - '0' The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA 32 4 High risk of mortality ↓ 64 8 Patient Directed to Department for Most Appropriate Care (e.g., ICU, Step-Down, Floor, etc.) 128 10 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 5#6SymphonyTM Aims to Transform Standard of Care with Rapid, Near-Patient Testing Enables Physicians to make actionable treatment decisions earlier for patient stratification Current Testing Methods: Time is the Enemy Significantly longer result turnaround times minimizes utility for critical care Require highly trained technicians to operate Large equipment located in central lab settings ● ● ● Symphony's Differentiated Features: Faster results to actionable decisions Quantitative, lab quality results System utilizes whole blood (no pre-processing required) Mobile, near-patient system ● ● ● ● bluejay DIAGNOSTICS Physician orders test Patient (critical care setting) Physician orders test 4 Patient (ICU/long-term care setting) The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Blood drawn from patient Turnaround time: several hours Physician uses test results to guide treatment Blood drawn from patient Turnaround time: ~20 minutes Blood sample transported to testing site Physician uses test results to guide treatment Lab results reported back to physician Sample processed near patient Symphony Stery Symphony Symphony™ System Sample processed at central testing site Central Testing Lab Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 6#7Symphony™ Platform: Rapid, Easy to Use Test System Being Developed for Patient Risk Stratification in Critical Care Settings ●●● bluejay Symphany Symphony Runs up to 6 tests simultaneously Fluorescence-based immunoanalyzer Designed for portable use No specialized training to operate The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Symphony by Symphery SymphonyTM Cartridges No additional chemicals No pre-processing of samples Advanced microfluidics nanotechnology ELISA = Enzyme-Linked Immunosorbent Assay Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 7#8IL-6 is ideal biomarker for earlier detection of sepsis severity Utility has been limited due to instability of IL-6 levels in patient samples over time ▶ Ideal Sepsis biomarkers: ●●● ● IL-6 is immune biomarker with potential for earlier detection IL-6 levels elevate early in blood IL-6 levels correlate with disease severity and survival in sepsis patients IL-6 levels over time offers quick snapshots of disease progression ● Correlate with disease severity Consistent with current standards of care Appear early enough to guide effective treatments IL-6 levels need to be read quickly to be accurate IL-6 levels change over time in patient samples and become clinically irrelevant ● Symphony IL-6 near patient assay drastically reduces time between when sample is taken and processed bluejay DIAGNOSTICS 1: J Clin Lab Anal. 2019 Sep; 33(7): e22924. Published online 2019 May 26. doi: 10.1002/jcla.22924 PMCID: PMC6757116PMID: 31131487 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 8#9Symphony™M IL-6 Test: Platform Potential for Rapid Results in Critical Care Settings Quantitative determination of IL-6 by fluorescence enzyme immunoassay from whole blood specimens ●●● bluejay DIAGNOSTICS Measuring IL-6 could help medical professionals make earlier and actionable treatment decisions. Rapid turnaround time crucial as 'time is the enemy' in critical care settings. Interleukin-6 (IL-6) is an Early Responder Biomarker During Trauma or Infection. Important in: Sepsis And Covid-19 Cardiovascular Diseases Autoimmune Disorders The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Multi-organ-Failure Acute Respiratory Distress Syndrome (ARDS) Infectious Disease Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 9#10The Commercial Opportunity: A Potential $1.2 Billion Total Addressable IL-6 Testing Market in Acute Care Settings (US Annual) Potential testing revenue from IL-6 testing in long-term acute care facilities (LTACs), emergency departments (EDs), and intensive care units (ICUS) DESCRIPTION Number of patients Percentage of patients with clinician ordered IL-6 tests³ Average number of IL-6 tests ordered for each patient³ Estimated number of IL-6 tests performed Cost per test to the lab4 Total Addressable Market for IL-6 testing Testing increase expected with Bluejay's Symphony IL-6 test³ Total Addressable Market with Bluejay's Symphony IL-6 test ●●● 00 DIAGNOSTICS LTACS 400,000¹ 27.5% 3.4 0.37 M $150 $56.1 M 26.4% $70.9 M 1 Harmony Healthcare: https://harmony.solutions/understanding-care-long-term-acute-care-hospitals-101/ 2National Center for Health Statistics, National Hospital Ambulatory Medical Care Survey, 2020 3Frost & Sullivan primary research 4Bluejay pricing expectations per IL-6 test under DRG coding The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA ICUS 3,100,000² 26.5% 3.7 3.0 M $150 $453.5 M 57.7% $714.9 M Bluejay's Symphony has potential to expand use of IL-6 testing in acute care settings: increase testing volumes by 54.6% raise TAM to $1.8 B EDS 5,345,000² 23.5% 3.5 4.4 M $150 $663.2 M 54.9% $1,027.3 M Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 10#11Symphony™M IL-6 Potential Clinical Advantages v. Current Tests Used for Sepsis Patients IL-6 negative predictive value (NPV) superior to other standard biomarkers Interleukin-6 (IL-6) 0.801 Metric Area Under Receiver Operator Characteristic Curve (AUC) ●●● Youden Index Cutoff Sensitivity Specificity NPV 1.52 bluejay DIAGNOSTICS 35 pg/mL 0.89 (0.65, 0.99) 0.64 (0.55, 0.72) 0.98 (0.92, 1.00) C-Reactive Protein (CRP) 0.578 1.35 113.95 mg/mL 0.44 (0.22, 0.69) 0.91 (0.84, 0.95) 0.92 (0.86, 0.96) Lactate 0.680 1.29 1.75 mmol/L 0.56 (0.31, 0.78) 0.74 (0.61, 0.84) 0.85 (0.72, 0.93) Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Sensitivity 1.0- 0.8- 0.6- 0.4- 0.2- 0.0- 1.0 ROC Curves of Biomarker Prediction of IMV 0.8 0.6 IL-6 (AUC = 0.801) CRP (AUC = 0.578) Lactate (AUC = 0.680) 0.4 Specificity Bluejay clinical study assessed ability of Symphony IL-6 to predict risk for invasive mechanical ventilation (IMV) in COVID-19 patients at time of hospital admission Favorable clinical performance demonstrated 89% sensitivity, 64% specificity and 98% NPV, which highlights potential higher clinical utility of IL-6 compared to other standard biomarkers to identify patients at future risk of IMV. IMV is associated with respiratory failure, which is common in sepsis patients. 0.2 0.0 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 11#12SymphonyTM Product Pipeline Well-validated critical care biomarkers. Tests with potential clinical and cost-saving benefits gained from faster turnaround times Products TM Symphony ™M IL-6 Test patient acuity for sepsis triage/monitoring Symphony TM hsTNT/I patient acuity with chest pain TM Symphony ™M NT-proBNP patient acuity with chest pain DIAGNOSTICS Research Development The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Clinical Testing New Tests Will Follow the IL-6 Development Pathway Regulatory Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 12#13Symphony IL-6 Regulatory Timeline for Sepsis to Reach Commercialization ●●● ●● Q4 '21 Initial clinical trials bluejay DIAGNOSTICS Q2 '22 FDA feedback; including de novo designation Q1 '22 Filed FDA pre-submission Q4 '22 Filed pre-submission supplement with FDA Q3 '22 Completed initial clinical trials Q1 '23 FDA feedback; study expansion required Q4 '22 Expanded trials to support de novo submission H1 24 Planned 510(k) FDA submission Q2 '23 Modify trial inclusion to obtain more patient data 2025 Planned commercialization We estimate there will be an incremental capital need of about $15 million to get through FDA approval Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 13#14SymphonyTM System Commercial Advantages¹ v. Central Lab Analyzer Systems for IL-6 ●●● Near Patient Test System Size Sample Type Advantages Separate Sample Processing Step Total Turnaround Time Requires Dedicated Personnel* System/Infrastructure Cost NPV2 for IL-6 Assay *(Phlebotomist/MedTech) bluejay DIAGNOSTICS Bluejay Symphony™ Near Patient Desktop Whole Blood No ~20 minutes No $ 98% Source: 1. Bluejay Diagnostics market research. 2. NPV = Negative Predictive Value. 3. Bluejay/Industry information, pending the location of the testing lab. 4. from FDA Emergency Use Authorization company filings The SymphonyTM System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Beckman, Siemens, Roche Central Lab Very Large Serum/Plasma Yes 4-48hr³ Yes $$$ 78.6-92.9%4 Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 14#15Launch Plan Starts by Converting Bluejay Clinical Trial Sites to Commercial Sites Existing multi-location healthcare testing sites are built-in initial commercial customers Stage 1 Clinical Study Testing Sites Stage 2 Convert testing sites to commercial sites Commercial Strategy Leveraging internal champions to drive adoption ::bluejay DIAGNOSTICS Stage 3 Expand to additional sites within same hospital system https://clinicaltrials.gov/study/NCT05048927?term=bluejay&intr-il-6&rank=4 Stage 4 Broaden commercialization to wider customer base beyond testing sites Consumables Model Cartridges provide recurring revenue and favorable margins August 2023 15#16Management & Advisors: Leadership, Diagnostic & Product Launch Expertise Indranil "Neil" Dey CEO and Co-founder Involved in introducing Her2neu test for Herceptin Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary, MBA (Fulbright Scholar) from Cambridge University, UK TM bluejay DIAGNOSTICS IMPATH The Cancer Information Company Kenneth Fisher Chief Financial Officer Responsible for finance, investor relations, accounting and administrative operations CPA; BA, Business Administration, Isenberg School of Management, University of Massachusetts at Amherst East Boston Savings Bank Jason Cook Chief Technology Officer Responsible for product development and manufacturing operations 15+ years in POC/ diagnostics product development Ph.D. in Biomedical Engineering, University of Texas at Austin D TEXAS The University of Texas at Austin Mark Feinberg Chief Medical Advisor Responsible for clinical development programs and strategic medical leadership Associate Professor, Harvard Medical School/Cardiovascular, Brigham & Women's; Medical College of Pennsylvania Brigham and Women's Hospital Founding Member, Mass General Brigham Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 16#17Board of Directors Douglas C. Wurth, Chairman Indranil "Neil" Dey, CEO Svetlana Dey Donald R. Chase Fred S. Zeidman Gary Gemignani J.P. Morgan ●●● ●● DIAGNOSTICS Skadden 20-year career at J.P. Morgan Chase (CEO of the International Private Bank & Alternative Investments, Asset Management) B.A Notre Dame University; J.D. University of Virginia School of Law; practiced law at Skadden, Arps, Meagher and Flom Involved in introducing Her2neu test for Herceptin and introduction of Erbitux Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary; MBA (Fulbright Scholar) from Cambridge University, UK Co-founder of Bluejay; President & CEO of LMBRI LLC; 15 years+ of management experience in healthcare industry Masters Degree in Mathematics from the State University of Mari El Republic, Russia 35 years in executive roles at well-known community banks in New England B.S. Accounting, Western New England University 50+ years of corporate advisory experience; Chairman Emeritus University of Texas Health Science System Bachelor's degree from Washington University in St. Louis; Masters in Business Administration from New York University Senior executive with experience in life sciences, public companies, accounting/finance Prior experience with Acacia Pharma, Biodel, Prudential Financial, Gentium, Novartis, Wyeth and Arthur Andersen IMPATH" The Con Company Imbri merchants BANCSHARES INC westbank UNITED STATES MUSEUM ARTHUR ANDERSEN Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 17#18Financial Highlights Financial Info (June 30, 2023) Cash* Est. Cash Runway Clean Balance Sheet BJDX (NASDAQ) (August 22, 2023) Market Cap Average Daily Trading Volume (30 day) Shares Outstanding Closing Price DIAGNOSTICS $5.1 M < 12 months No outstanding warrants or debt $7.6M 620K shares 1.0M $7.11 The Symphony™ System and SymphonyTM Cartridge have not been cleared or approved by the U.S. FDA Symphony Symphony L Symphony Symphony f yo Erbacity Sympheny 000 Kelanta Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 18#19Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203 Acton, MA 01720 Toll-free: 844.327.7078 Main: 978.631.4884 [email protected] Symphony Canpents 18-4dy comm Adat 2124 Wh HAP 1 FOR INVESTIGATIONAL USE REPT Vo bluejay Sympheny Symphony Symphony Onepa Improving Patient Outcomes In Critical Care Settings Developing cost-effective, rapid, near-patient diagnostic products utilizing the IL-6 biomarker Kan wyp bluejay DIAGNOSTICS#20Reference Library Sepsis Background Sepsis Alliance: World Health Organization: • ● ● II-6 Background ● ● ●●● https://www.who.int/news-room/fact-sheets/detail/sepsis Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. The Lancet Vol 395, Issue 10219, 18-24 Jan 2020, pp 200-211 https://www.sciencedirect.com/science/article/pii/S0140673619329897 https://www.sepsis.org/sepsis-basics/what-is-sepsis/ Plasma interleukin-6 levels correlate with survival in patients with bacterial sepsis and septic shock. Interv Med Appl Sci. 2021 Aug; 11(4): 224-230. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467384/ Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infectious Diseases volume 19, Article number: 968 (2019). https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4618-7 bluejay DIAGNOSTICS Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | August 2023 20